About US
Contact us
-
Cipla Medpro to market Teva’s pharmaceutical products in South AfricaCipla Medpro subsidiary Medpro Pharmaceutica has entered into an agreement with Teva Pharmaceuticals. As part of the deal, Medpro will exclusively market Teva's pharmaceutical product portfolio in So2014/10/10
-
Pfizer introduces new medicines optimisation scratch cardUS-based Pfizer has introduced a new scratch card in a bid to involve the public in medicines optimisation. The card has been designed to increase patient engagement with the pharmacy team and create2014/10/10
-
Cipla and S&D Pharma partner for business in Czech Republic and SlovakiaIndia-based Cipla has partnered with UK's S&D Pharma to launch affordable, high-quality alternatives in the Czech Republic and Slovakia. Under the deal, Cipla will introduce its respiratory produ2014/10/9
-
Merck to buy Sigma-Aldrich for $17bnUS-based Merck has signed an agreement to acquire Sigma-Aldrich for $17bn (€13.1bn), which will boost the company's position in the life science industry.Under the deal, Merck will acquire all outstan2014/10/9
-
AbbVie’s Humira receives FDA approval to treat Crohn’s disease in paediatric patientsAbbVie has received approval from the US Food and Drug Administration (FDA) for its Humira (adalimumab) to treat paediatric patients with moderately to severely active Crohn's disease. The drug has b2014/10/8
-
Patheon to Showcase its Complex Formulation Technologies Expertise at CPhI/ICSE - Japan ConferencePatheon personnel and scientific experts will be available to meet at the CPhI/ICSE - Japan conference in Tokyo from 9-11 April to discuss how Patheon can actively support pharmaceutical and biotech c2014/10/8
-
Patheon® to Feature API Development and Manufacturing Capabilities at CPhI/ICSE WorldwidePatheon is to showcase its biologic, small molecule API development services and manufacturing capabilities for finished dosage forms at CPhI / ICSE Worldwide from Tuesday 7 October to Thursday 9 Octo2014/10/8
-
Roche's Perjeta helps breast cancer patients live a record-setting 15.7 months longerThese days, even expensive cancer treatments don't necessarily deliver show-stopping study results when it comes to actually extending patients' lives. Roche's ($RHHBY)Perjetais now a major departure2014/9/30
-
ESMO: The latest skinny on drugs from Pfizer, Novartis, GSK, Merck, BMSThe European Society for Medical Oncology meeting may not be as enormous as its U.S. counterpart, but plenty of news is flowing. And some of the new data presented in Madrid over the weekend is pretty2014/9/30
-
Pfizer preps its case for FDA pulling Chantix's black-box warningThe FDA polished up the official label on Pfizer's stop-smoking drugChantixearlier this week. It was a victory for Pfizer ($PFE), the payoff from several studies testing the drug for psychiatric side2014/9/29